Theravance Biopharma Inc (TBPH) Stock Analysis

Theravance Biopharma Inc (TBPH) is a publicly traded company in the HEALTHCARE sector. It trades at $15.58, carries a market capitalization of $827.94M, a price-to-earnings ratio of 7.20. This page summarizes the public market data, fundamentals, and frequently asked questions for TBPH, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Theravance Biopharma Inc currently has a Bullish sentiment score of 0.16.

About Theravance Biopharma Inc

Theravance Biopharma, Inc. (TBPH) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative organ-selective drugs aimed at addressing significant unmet medical needs. With a strategic emphasis on respiratory diseases and conditions, Theravance leverages its proprietary technologies and deep scientific expertise to bring novel therapies to market, enhancing patient outcomes worldwide. Headquartered in George Town, Cayman Islands, the company oper...

GNG Research Analysis

GNG Research scores Theravance Biopharma Inc (TBPH) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TBPH.

Frequently Asked Questions

Does TBPH pay dividends?

Theravance Biopharma Inc (TBPH) does not currently pay a regular dividend.

What is TBPH's P/E ratio?

Theravance Biopharma Inc has a price-to-earnings (P/E) ratio of 7.20.

What is TBPH's market cap?

Theravance Biopharma Inc (TBPH) has a market capitalization of $827.94M with a current stock price of $15.58.